The purpose of this systematic review is to discuss recent studies and ongoing trials of nab-paclitaxel in breast cancer and to examine the potential role of nab-paclitaxel as a backbone for immuno-oncology therapies.
PubMed and selected congress proceedings were searched for studies of nab-paclitaxel in breast cancer published between 2013 and 2015. All phase II and III clinical trials, retrospective analyses, and institutional studies were included. Active, ongoing, phase II or III trials on nab-paclitaxel that were listed on ClinicalTrials.gov were also included.
Sixty-three studies, including 23 in early-stage and 30 in metastatic breast cancer (some studies not classifiable by setting), were included in this analysis. Trials of neoadjuvant nab-paclitaxel–containing regimens have reported pathological complete response rates ranging from 5.7 to 53%. Median overall survival in metastatic breast cancer studies ranged from 10.8 to 23.5 months, depending on dose and regimen. Adverse event profiles of nab-paclitaxel were generally similar to those reported from previous studies. Several ongoing trials are evaluating nab-paclitaxel in the early-stage and metastatic settings, including in combination with immuno-oncology agents.
nab-Paclitaxel continues to demonstrate promising efficacy in breast cancer. Recent studies demonstrate high pathological complete response rates in early-stage breast cancer, particularly in triple-negative breast cancer, an area of high unmet need, and encouraging overall survival in metastatic breast cancer across doses and schedules. Ongoing trials will provide further insights into the role of nab-paclitaxel in breast cancer including use as a potential backbone chemotherapy agent for immuno-oncology therapies such as checkpoint inhibitors.
Clinical practice guidelines in oncology: breast cancer. V2.2016. Fort Washington: National Comprehensive Cancer Network; 2016.
Abraxane for injectable suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) [package insert]. Summit: Celgene Corporation; 2015.
Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res. 2002;8:1038–44. PubMed
Huang L, Chen S, Yao L, Liu G, Wu J, Shao Z. Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer. Int J Nanomed. 2015;10:1969–75.
Shigematsu H, Kadoya T, Masumoto N, Sasada T, Emi A, Ohara M, et al. The efficacy and safety of preoperative chemotherapy with triweekly abraxane and cyclophosphamide followed by 5-fluorouracil, epirubicin, and cyclophosphamide therapy for resectable breast cancer: a multicenter clinical trial. Clin Breast Cancer. 2015;15:110–6. CrossRefPubMed
Khan QJ, O’Dea A, Fabian CJ, Connor CS, McGinness M, Varghise Mammen JM, et al. Neoadjuvant chemotherapy plus trastuzumab in stage II/III breast cancer with low HER2 expression. J Clin Oncol. 2015;33(suppl). Abstract 1039.
Martin M, Antolín S, Anton A, Plazaola A, García-Martínez E, Seguí MA, et al. Nabrax: neoadjuvant therapy of breast cancer with weekly single-agent nab-paclitaxel—final efficacy and biomarkers analysis of GEICAM 2011-02 trial. J Clin Oncol. 2014;32(suppl). Abstract 1051.
Nahleh ZA, Barlow WE, Hayes DF, Schott AF, Gralow JR, Perez EA, et al. S0800: nab-paclitaxel, doxorubicin, cyclophosphamide, and pegfilgrastim with or without bevacizumab in treating women with inflammatory or locally advanced breast cancer. Poster presented at: 37th annual San Antonio breast cancer symposium. San Antonio; 2014. Abstract P3-11-16.
Hofmann D, Nitz U, Gluz O, Kates RE, Schinkoethe T, Staib P, et al. WSG ADAPT—adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial. Trials. 2013;14:261. CrossRefPubMedPubMedCentral
Gluz O, Nitz U, Christgen M, Grischke E, Forstbauer H, Braun MW, et al. Efficacy of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG-ADAPT TN randomized phase II trial. J Clin Oncol. 2015;33(suppl). Abstract 1032.
Gluz O, Nitz U, Liedtke C, Christgen M, Sotlar K, Grischke EM, et al. Comparison of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple- negative breast cancer: WSG-ADAPT TN randomized phase II trial. Presented at: 38th annual San Antonio breast cancer symposium. San Antonio; 2015. Abstract S6-07.
Kuwayama T, Yamauchi H, Takano T, Tsugawa K, Sato T, Kitani A, et al. Primary analysis of a randomized phase II, multicenter trial: Neoadjuvant weekly nab-paclitaxel 100 mg/m 2 followed by FE100C compared with docetaxel 75 mg/m 2 followed by FE100C for early breast cancer in Japan. Presented at: 2015 breast cancer symposium. San Francisco; 2015. Abstract 136.
Shimada H, Ueda S, Saeki T, Shigekawa T, Takeuchi H, Hirokawa E, et al. Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for stage II/III HER2-negative breast cancer: evaluation of efficacy and safety. Jpn J Clin Oncol. 2015;45:642–9. CrossRefPubMed
Sinclair NF, Sakr BJ, Abu-Khalaf MM, Somlo G, Black RC, Chung GG, et al. Multicenter phase II trial of neoadjuvant carboplatin, weekly nab-paclitaxel, and trastuzumab in stage II-III HER2+ breast cancer: a BrUOG study. J Clin Oncol. 2013;31(suppl). Abstract 619.
Tanaka S, Iwamoto M, Kimura K, Matsunami N, Morishima H, Yoshidome K, et al. Phase II study of neoadjuvant anthracycline-based regimens combined with nanoparticle albumin-bound paclitaxel and trastuzumab for human epidermal growth factor receptor 2-positive operable breast cancer. Clin Breast Cancer. 2015;15:191–6. CrossRefPubMed
Avril S, Varadan V, Miskimen K, Gollamudi J, Abu-Khalaf MM, Somlo G, et al. Association of tumor infiltrating lymphocytes (TILs) with pathologic response in baseline and post-brief exposure HER2+ breast cancer biopsies from BrUOG. J Clin Oncol. 2015;33(suppl). Abstract 619.
von Minckwitz G, Conrad B, Reimer T, Decker T, Eidtmann H, Eiermann W, et al. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52). Cancer. 2015;121:3639–48. CrossRef
Möbus V, Lück H, Forstbauer H, Wachsmann G, Ober A, Schneeweiss A, et al. GAIN-2: adjuvant phase III trial to compare intense dose-dense (idd) treatment with EnPC to tailored dose-dense (dt) therapy with dtEC-dtD for patients with high-risk early breast cancer: results of the second safety interim analyses. Presented at: 38th annual San Antonio breast cancer symposium. San Antonio; 2015. Abstract P1-13-05.
Loman N, Linderholm B, Joensuu H, Ejlertsen B, Johannsson OT, Geisler J, et al. Nordic trip, a randomized phase 3 study in early triple negative breast cancer. Presented at: 38th annual San Antonio breast cancer symposium. San Antonio; 2015. Abstract OT3-02-10.
Rugo HS, Barry WT, Moreno-Aspitia A, Lyss AP, Cirrincione C, Leung E, et al. Randomized phase III trial of paclitaxel once per week compared with nanoparticle albumin-bound nab-paclitaxel once per week or ixabepilone with bevacizumab as first-line chemotherapy for locally recurrent or metastatic breast cancer: CALGB 40502/NCCTG N063H (Alliance). J Clin Oncol. 2015;33:2361–9. CrossRefPubMedPubMedCentral
Sun S, Tang L, Zhang J, Lv F, Wang Z, Wang L, et al. Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer. Int J Nanomed. 2014;9:1443–52.
Jain MM, Gupte SU, Patil SG, Pathak AB, Deshmukh CD, Bhatt N, et al. Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: a multicenter, randomized, comparative phase II/III study. Breast Cancer Res Treat. 2016;156:125–34. CrossRefPubMedPubMedCentral
Jackisch C, Untch M, Dall P, Thomssen C, Albert U-S, Lueck HJ, et al. A national treatment survey on the chemotherapy (CTX) treatment for patients (pts) with metastatic breast cancer (MBC) in Germany. J Clin Oncol. 2013;31(suppl). Abstract e17544.
Force RW, Pugmire BA, Binder G, Duval C, Corzo D, Gluck S. Differences between taxanes in time on therapy and associated discontinuation events in metastatic breast cancer: results from a US claims analysis. Presented at: 2013 breast cancer symposium. San Francisco; 2013. Abstract 158.
Forero-Torres A, Varley KE, Abramson VG, Li Y, Vaklavas C, Lin NU, et al. TBCRC 019: a phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 monoclonal antibody tigatuzumab in patients with triple-negative breast cancer. Clin Cancer Res. 2015;21:2722–9. CrossRefPubMed
Palumbo R, Sottotetti F, Trifiro G, Piazza E, Ferzi A, Gambaro A, et al. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life. Drug Des Dev Ther. 2015;9:2189–99. CrossRef
Lazzaro C, Bordonaro R, Cognetti F, Fabi A, De Placido S, Arpino G, et al. An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study. Clinicoecon Outcomes Res. 2013;5:125–35. CrossRefPubMedPubMedCentral
Nilsson A, Lundkvist J, Lindman H. Time and value of chemotherapy administration burden in a Swedish hospital. Presented at: 38th annual San Antonio breast cancer symposium. San Antonio; 2015. Abstract P6-11-06.
Bachelot TD, Ciruelos E, Peretz-Yablonski T, Puglisi F, Schneeweiss A, Campone M, et al. First-line pertuzumab (P), trastuzumab (H), and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC): interim safety results (N = 704) from PERUSE. J Clin Oncol. 2014;32(suppl). Abstract 548.
Woodward N, De Boer RH, Redfern A, Von Neumann-Cosel V, Heath RM, Beith J. An open-label, multicentre, phase IIIb study with intravenous administration of pertuzumab, subcutaneous trastuzumab, and a taxane in patients with HER2-positive metastatic breast cancer (SAPPHIRE). Presented at: 37th annual San Antonio breast cancer symposium. San Antonio; 2014. Abstract OT3-1-03.
Woodward N, De Boer RH, Redfern A, White M, Young J, Truman M, et al. Interim results from the first open-label, multicenter, phase IIIb study investigating the combination of pertuzumab with subcutaneous trastuzumab and a taxane in patients with HER2-positive metastatic breast cancer (SAPPHIRE). Presented at: 38th annual San Antonio breast cancer symposium. San Antonio; 2015. Abstract P4-14-12.
Patel TA, Mejia JA, Rodriguez AA, Chee Ning Chang J. Phase Ib trial of trastuzumab emtansine (TE) in combination with lapatinib (L) plus nab-paclitaxel in metastatic HER2-neu overexpressed breast cancer patients: STELA trial. J Clin Oncol. 2014;32(suppl). Abstract TPS669.
Yardley DA, Brufsky A, Coleman RE, Conte PF, Cortes J, Glück S, et al. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Trials. 2015;16:575. CrossRefPubMedPubMedCentral
Gennari A, Jerusalem G, Maibach R. The SNAP trial: schedules of nab-paclitaxel in metastatic breast cancer, International Breast Cancer Study Group (IBCSG 42-12) and Breast International Group (BIG 2-12). Poster presented at: 36th annual San Antonio breast cancer symposium. San Antonio; 2013. Abstract OT3-1-02.
Avery TP, Jaslow R, Basu-Mallick A, Zibelli A, Fellin F, Cristofanilli M. A phase I study of romidepsin in combination with nab-paclitaxel in patients with metastatic HER-2 negative inflammatory breast cancer (IBC). Presented at: 38th annual San Antonio breast cancer symposium. San Antonio; 2015. Abstract P4-13-18.
Chia SK. Neoadjuvant and adjuvant therapy for HER2 positive disease. Am Soc Clin Oncol Educ Book. 2015;31:e41–8. CrossRef
Camidge DR, Liu SV, Powderly J, Ready NE, Hodi FS, Gettinger SN, et al. Atezolizumab (MPDL3280A) combined with platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a phase Ib safety and efficacy update. J Thorac Oncol. 2015;10(9 suppl):S176–7.
Adams S, Diamond J, Hamilton E, Pohlmann P, Tolaney S, Molinero L, et al. Safety and clinical activity of atezolizumab (anti-PDL1) in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer. Presented at: 38th annual San Antonio breast cancer symposium. San Antonio; 2015. Abstract P2-11-06.
Emens L, Adams S, Loi S, Schmid P, Schneeweiss A, Rugo H, et al. A phase III randomized trial of atezolizumab in combination with nab-paclitaxel as first line therapy for patients with metastatic triple-negative breast cancer (mTNBC). Presented at: 38th annual San Antonio breast cancer symposium. San Antonio; 2015. Abstract OT1-01-06.
Seki H, Asamuna F, Morinaga S, Suzuki K, Kaneda M, Kamiya N, et al. Weekly nab-paclitaxel followed by FEC in patients with operable breast cancer: phase II study. J Clin Oncol. 2015;33(suppl). Abstract 138.
Khasraw M, Mukaro VR, West L, Brandt C, Woollett AM, Edwards M, et al. Tailored neoadjuvant epirubicin and cyclophosphamide (EC) and nanoparticle albumin bound (nab)-paclitaxel for newly diagnosed breast cancer (BC). J Clin Oncol. 2015;33(suppl). Abstract e12025.
Tsugawa K, Kawamoto H, Kojima Y, Tsuchiya K, Shimo A, Hayami R, et al. Feasibility study of weekly nanoparticle albumin-bound (nab)-paclitaxel (150 mg/m 2) followed by 5FU, epirubicin, plus cyclophosphamide (FEC) as neoadjuvant chemotherapy for HER2-negative breast cancer. Poster presented at: 9th European breast cancer conference. Glasgow; 2014. Abstract 43.
Somlo G, Frankel P, Li M, Treece T, Kruper L, Yim J, et al. Phase II trial of neoadjuvant chemotherapy with carboplatin and nab-paclitaxel in patients with triple negative locally advanced and inflammatory breast cancer (TNBC). Poster presented at: 38th annual San Antonio breast cancer symposium. San Antonio; 2015. Abstract P1 14-10.
Mrozek E, Layman R, Ramaswamy B, Lustberg M, Vecchione A, Knopp MV, et al. Phase II trial of neoadjuvant weekly nanoparticle albumin-bound paclitaxel, carboplatin, and biweekly bevacizumab therapy in women with clinical stage II or III HER2-negative breast cancer. Clin Breast Cancer. 2014;14:228–34. CrossRefPubMedPubMedCentral
Matsuda N, Alvarez RH, Krishnamurthy S, Willey JS, Wang X, Lim B, et al. Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER-2 negative inflammatory breast cancer. J Clin Oncol. 2015;33(suppl). Abstract 1065.
Aigner J, Marme F, Smetanay K, Schuetz F, Jaeger D, Schneeweiss A. Nab-paclitaxel monotherapy as a treatment of patients with metastatic breast cancer in routine clinical practice. Anticancer Res. 2013;33:3407–13. PubMed
Moebus V, Forstbauer H, Wachsmann G, Schneeweiss A, Ober A, von Abel E, et al. Adjuvant phase III trial to compare intense dose-dense adjuvant treatment with EnPC to dose dense, tailored therapy with dtEC-dtD for patients with high-risk early breast cancer (GAIN-2). J Clin Oncol. 2013;31(suppl). Abstract TPS1137.
- nab-Paclitaxel for the treatment of breast cancer: an update across treatment settings
- BioMed Central
Neu im Fachgebiet Onkologie
Mail Icon II